Effect of supplement with lactic-acid producing bacteria on fatigue and physical activity in patients with chronic fatigue syndrome

Nutrition Journal

Volumn 8, Issue 1, 2009, Pages

  Sullivan, Åsa ^a   Nord, Carl E ^a   Evengård, Birgitta ^a,b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UMEÅ UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CALGRANULIN; LACTIC ACID; PROBIOTIC AGENT;

ADULT; ARTICLE; BIFIDOBACTERIUM ANIMALIS; CHRONIC FATIGUE SYNDROME; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COGNITION; DISEASE SEVERITY; DRUG EFFICACY; FATIGUE; FECES ANALYSIS; FEMALE; FOLLOW UP; HEALTH STATUS; HUMAN; INTESTINE FLORA; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS PARACASEI; MALE; NEUROLOGIC EXAMINATION; PHYSICAL ACTIVITY; PHYSICAL DISABILITY; SHORT FORM 12; TREATMENT OUTCOME; VISUAL ANALOG SCALE; BIFIDOBACTERIUM; CHEMISTRY; DIET SUPPLEMENTATION; FECES; LACTOBACILLUS; MICROBIOLOGY; MIDDLE AGED; MOTOR ACTIVITY; PILOT STUDY; PSYCHOLOGICAL ASPECT;

BIFIDOBACTERIUM ANIMALIS SUBSP. LACTIS; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS PARACASEI;

ADULT; BIFIDOBACTERIUM; DIETARY SUPPLEMENTS; FATIGUE; FATIGUE SYNDROME, CHRONIC; FECES; FEMALE; HUMANS; LACTOBACILLUS; LACTOBACILLUS ACIDOPHILUS; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; MIDDLE AGED; MOTOR ACTIVITY; PILOT PROJECTS; PROBIOTICS;

EID: 60849105671     PISSN: None     EISSN: 14752891     Source Type: Journal    
DOI: 10.1186/1475-2891-8-4     Document Type: Article

References (33)

1. The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. K Fukuda SE Straus I Hickie MC Sharpe JG Dobbins A Komaroff, Ann Intern Med 1994 121 953 9 7978722
2. Identification of ambiguities in the 1994 chronic fatigue syndrome research case definition and recommendations for resolution. WC Reeves A Lloyd SD Vernon N Klimas LA Jason G Bleijenberg B Evengard PD White R Nisenbaum ER Unger, BMC Health Serv Res 2003 3 25 14702202 10.1186/1472-6963-3-25
3. Epidemiology of chronic fatigue syndrome. G Ranjith, Occup Med (Lond) 2005 55 13 9 10.1093/occmed/kqi012 15699086
4. The epidemiology of chronic fatigue in the Swedish twin registry. B Evengard A Jacks NL Pedersen PF Sullivan, Psychological Medicine 2005 35 1 10 10.1017/S0033291704004052
5. Chronic fatigue syndrome: probable pathogenesis and possible treatments. B Evengard N Klimas, Drugs 2002 62 2433 46 10.2165/00003495-200262170-00003 12421101
6. Chronic fatigue syndrome (cfs). RH Adler, Swiss Med Wkly 2004 134 268 76 15243847
7. Cytokines and chronic fatigue syndrome. R Patarca, Ann N Y Acad Sci 2001 933 185 200 12000020
8. Symptom patterns in long-duration chronic fatigue syndrome. F Friedberg L Dechene MJ McKenzie 2nd R Fontanetta, J Psychosom Res 2000 48 59 68 10.1016/S0022-3999(99)00077-X 10750631
9. Systematic review of the comorbidity of irritable bowel syndrome with other disorders: what are the causes and implications? WE Whitehead O Palsson KR Jones, Gastroenterology 2002 122 1140 56 10.1053/gast.2002.32392 11910364
10. AGA technical review on irritable bowel syndrome. DA Drossman M Camilleri EA Mayer WE Whitehead, Gastroenterology 2002 123 2108 31 10.1053/gast.2002. 37095 12454866
11. A review of the role of the gut microflora in irritable bowel syndrome and the effects of probiotics. JA Madden JO Hunter, Br J Nutr 2002 88 Suppl 1 S67 72 10.1079/BJN2002631 12215182
12. 'Bacterial colonosis' in patients with persistent fatigue. HL Butt RH Dunstan NR McGregor TK Roberts, Proceedings of the AHMF International Clinical and Scientific Conference; Sydney, Australia
13. Elevated levels of Candida albicans in the faecal microflora of chronic fatigue syndrome patients during the acute phase of illness. B Evengård H Gräns E Wahlund CE Nord, Scand J Gastroent 2007
14. Chronic fatigue syndrome: oxidative stress and dietary modifications. AC Logan C Wong, Altern Med Rev 2001 6 450 9 11703165
15. Probiotics and gastrointestinal diseases. A Sullivan CE Nord, J Intern Med 2005 257 78 92 10.1111/j.1365-2796.2004.01410.x 15606379
16. Treatment of irritable bowel syndrome with Lacteol Fort: a randomized, double-blind, cross-over trial. GM Halpern T Prindiville M Blankenburg T Hsia ME Gershwin, Am J Gastroenterol 1996 91 1579 85 8759665
17. A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome. K Niedzielin H Kordecki B Birkenfeld, Eur J Gastroenterol Hepatol 2001 13 1143 7 10.1097/00042737-200110000-00004 11711768
18. Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. S Nobaek ML Johansson G Molin S Ahrne B Jeppsson, Am J Gastroenterol 2000 95 1231 8 10.1111/j.1572-0241.2000.02015.x 10811333
19. Effect of Lactobacillus plantarum 299v on colonic fermentation and symptoms of irritable bowel syndrome. S Sen MM Mullan TJ Parker JT Woolner SA Tarry JO Hunter, Dig Dis Sci 2002 47 2615 20 10.1023/A:1020597001460 12452404
20. Bacterial supplementation in the irritable bowel syndrome. A randomised double-blind placebo-controlled crossover study. O'Sullivan MA O'Morain CA, Dig Liver Dis 2000 32 294 301 10.1016/S1590-8658(00)80021-3 11515626
21. Antioxidative ability of lactic acid bacteria. MY Lin CL Yen, J Agric Food Chem 1999 47 1460 6 10.1021/jf981149l 10563999
22. Lactobacilli from human gastrointestinal mucosa are strong stimulators of IL-12 production. C Hessle LA Hanson AE Wold, Clin Exp Immunol 1999 116 276 82 10337019 10.1046/j.1365-2249.1999.00885.x
23. Can immunoregulatory lactic acid bacteria be used as dietary supplements to limit allergies? ML Cross HS Gill, Int Arch Allergy Immunol 2001 125 112 9 10.1159/000053804 11435727
24. Probiotics: a novel approach in the management of food allergy. H Majamaa E Isolauri, J Allergy Clin Immunol 1997 99 179 85 10.1016/S0091-6749(97)70093-9 9042042
25. Chronic fatigue syndrome: lactic acid bacteria may be of therapeutic value. AC Logan A Venket Rao D Irani, Med Hypotheses 2003 60 915 23 10.1016/S0306-9877(03)00096-3 12699726
26. The visual analogue pain intensity scale: what is moderate pain in millimetres? SL Collins RA Moore HJ McQuay, Pain 1997 72 95 7 10.1016/S0304-3959(97)00005-5 9272792
27. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. JE Ware Jr CD Sherbourne, Med Care 1992 30 473 83 10.1097/00005650-199206000-00002 1593914
28. Fecal calprotectin levels in healthy children studied with an improved assay. UL Fagerberg L Loof RD Merzoug LO Hansson Y Finkel, J Pediatr Gastroenterol Nutr 2003 37 468 72 10.1097/00005176-200310000-00013 14508218
29. Effect of lactobacillus F19 on the emergence of antibiotic-resistant microorganisms in the intestinal microflora. Å Sullivan A Johansson B Svenungsson CE Nord, J Antimicrob Chemother 2004 54 791 7 10.1093/jac/dkh406 15329362
30. Enumeration and identification of Lactobacillus paracasei subsp. paracasei F19. S Björneholm A Eklöw M Saarela J Mättö Microbial Ecology in Health and Disease 2002 Suppl 3 7 13 10.1080/ 089106002760003288
31. The economic impact of chronic fatigue syndrome. KJ Reynolds SD Vernon E Bouchery WC Reeves, Cost Eff Resour Alloc 2004 2 4 15210053 10.1186/1478-7547-2- 4
32. The placebo response in the treatment of chronic fatigue syndrome: a systematic review and meta-analysis. HJ Cho M Hotopf S Wessely, Psychosom Med 2005 67 301 13 10.1097/01.psy.0000156969.76986.e0 15784798
33. Chronic fatigue syndrome: the need for subtypes. LA Jason K Corradi S Torres-Harding RR Taylor C King, Neuropsychol Rev 2005 15 29 58 10.1007/s11065-005-3588-2 15929497